Agents targeting the p19 subunit of the IL-23 cytokine pathway have been approved for treatment only for 3 years, so the data for the incidence of MACEs in the clinical trials for the safety profile of IL-23p19 inhibitors is not sufficient to determine its influence on the cardiovascular risk of psoriasis patients (Blauvelt et al., 2017; Papp et al., 2017). This evidence concerns the gene IL23A and psoriasis.